Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Wishing to Launch Drugs in Japan within 6 Months of the 1st Launch Overseas: Dr Kato of AstraZeneca
August 6, 2001
- GSK, Shionogi to Establish Overseas Joint Venture
August 6, 2001
- REGULATORY NEW IN BRIEF
August 6, 2001
- Taiho Aims at Becoming World Leader in Oncology: Mid-term Plan
August 6, 2001
- Blood Glucose Control Improved by Ultra-fast Acting Insulin: Lilly Symposium
August 6, 2001
- Nippon Kayaku to Place Top Priority on R&D
August 6, 2001
- Large Studies Required to Verify Inhibition of Cardiovascular Events: Sankyo Seminar
August 6, 2001
- Morishita Jintan to Expand Seamless Microcapsule Business
August 6, 2001
- Saitama Medical School to Establish Genomic Medicine Research Center
August 6, 2001
- Pfizer to Increase Number of MRs to 2,300 in 2005: Survey
August 6, 2001
- Many Physicians Prescribe Medium/High-Dose Pill: User Education Needed
August 6, 2001
- BUSINESS NEWS IN BRIEF
August 6, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
August 6, 2001
- Yoshitomi to Focus Only on Psychiatric Field
August 6, 2001
- Dr Kawakita Urges Medical Facilities to Improve Quality of Services: Seminar
August 6, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
August 6, 2001
- Kenporen to Cooperate with Nikkeiren, Rengo in Healthcare Reform
August 6, 2001
- CRO Business Expanding Rapidly: Association Report
August 6, 2001
- Chamber Councils Selection System to Be Started in Medical Malpractice Suits
August 6, 2001
- Kasamatsu Meiki, Hokuho Iyaku to Merge on Oct. 1
August 6, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…